Last reviewed · How we verify
Tenofovir alafenamide(TAF)
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing viral replication.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor that blocks HIV reverse transcriptase, preventing viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based dosing).
At a glance
| Generic name | Tenofovir alafenamide(TAF) |
|---|---|
| Also known as | VEMLIDY® |
| Sponsor | Humanity and Health Research Centre |
| Drug class | Nucleotide reverse transcriptase inhibitor (NtRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TAF is a prodrug of tenofovir that is activated intracellularly to tenofovir diphosphate, which inhibits HIV reverse transcriptase and prevents conversion of viral RNA to DNA. It achieves higher intracellular concentrations with lower systemic exposure compared to tenofovir disoproxil fumarate (TDF), resulting in improved tolerability and reduced nephrotoxicity and bone loss.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based dosing)
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Elevated creatinine kinase
Key clinical trials
- Spotting Syphilis: A Dual Point-of-Care Syphilis Screening Initiative in a Low-Resource Healthcare Setting (NA)
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018) (PHASE3)
- Early Metabolic Effects of Dolutegravir or Tenofovir Alefenamide in Healthy Volunteers (PHASE2)
- Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1 (PHASE2, PHASE3)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE: A Multi-Center, Single-Arm, Open-Label, Phase 4 Study Assessing the Safety and Efficacy of B/F/TAF in HIV-Positive Adults Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks (PHASE4)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir alafenamide(TAF) CI brief — competitive landscape report
- Tenofovir alafenamide(TAF) updates RSS · CI watch RSS
- Humanity and Health Research Centre portfolio CI